TN2014000068A1 - Compounds and compositions as c-kit kinase inhibitors - Google Patents
Compounds and compositions as c-kit kinase inhibitorsInfo
- Publication number
- TN2014000068A1 TN2014000068A1 TNP2014000068A TN2014000068A TN2014000068A1 TN 2014000068 A1 TN2014000068 A1 TN 2014000068A1 TN P2014000068 A TNP2014000068 A TN P2014000068A TN 2014000068 A TN2014000068 A TN 2014000068A TN 2014000068 A1 TN2014000068 A1 TN 2014000068A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compounds
- kinase inhibitors
- compositions
- kit
- kit kinase
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 3
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- 101150038994 PDGFRA gene Proteins 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530038P | 2011-09-01 | 2011-09-01 | |
| PCT/US2012/052802 WO2013033167A1 (en) | 2011-09-01 | 2012-08-29 | Compounds and compositions as c-kit kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2014000068A1 true TN2014000068A1 (en) | 2015-07-01 |
Family
ID=46829904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2014000068A TN2014000068A1 (en) | 2011-09-01 | 2014-02-17 | Compounds and compositions as c-kit kinase inhibitors |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8569283B2 (enExample) |
| EP (1) | EP2751104B1 (enExample) |
| JP (1) | JP6134319B2 (enExample) |
| KR (1) | KR101962495B1 (enExample) |
| CN (1) | CN103797011B (enExample) |
| AP (1) | AP2014007493A0 (enExample) |
| AR (1) | AR087753A1 (enExample) |
| AU (1) | AU2012302042B2 (enExample) |
| BR (1) | BR112014004560A2 (enExample) |
| CA (1) | CA2845169C (enExample) |
| CL (1) | CL2014000492A1 (enExample) |
| CO (1) | CO6900141A2 (enExample) |
| CR (1) | CR20140107A (enExample) |
| CU (1) | CU20140024A7 (enExample) |
| EA (1) | EA026152B1 (enExample) |
| ES (1) | ES2761332T3 (enExample) |
| GT (1) | GT201400034A (enExample) |
| IL (1) | IL231227A0 (enExample) |
| MA (1) | MA35460B1 (enExample) |
| MX (1) | MX339937B (enExample) |
| PE (1) | PE20140909A1 (enExample) |
| PH (1) | PH12014500372A1 (enExample) |
| PL (1) | PL2751104T3 (enExample) |
| PT (1) | PT2751104T (enExample) |
| SG (1) | SG2014014369A (enExample) |
| TN (1) | TN2014000068A1 (enExample) |
| TW (1) | TW201313717A (enExample) |
| UY (1) | UY34301A (enExample) |
| WO (1) | WO2013033167A1 (enExample) |
| ZA (1) | ZA201401175B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6134319B2 (ja) | 2011-09-01 | 2017-05-24 | ノバルティス アーゲー | ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物 |
| US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| DK3007689T3 (en) | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| JP6483714B2 (ja) | 2013-10-11 | 2019-03-13 | ローレンス エス． ジスマン， | 噴霧乾燥製剤 |
| US20150288928A1 (en) * | 2014-04-08 | 2015-10-08 | Sony Corporation | Security camera system use of object location tracking data |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| MA42293A (fr) | 2015-07-02 | 2018-05-09 | Janssen Sciences Ireland Uc | Composés antibactériens |
| US10474987B2 (en) * | 2015-08-05 | 2019-11-12 | Whirlpool Corporation | Object recognition system for an appliance and method for managing household inventory of consumables |
| US20190256509A1 (en) * | 2016-06-08 | 2019-08-22 | Chrysalis, Inc. | Histone demethylase inhibitors |
| EP3472158A1 (en) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacterials |
| EP3472152A1 (en) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacte rials |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| JP2020500183A (ja) | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | 肺高血圧症の治療のための併用療法 |
| US20180162291A1 (en) * | 2016-12-12 | 2018-06-14 | Wipro Limited | System and method of dynamically adjusting field of view of an image capturing device |
| CN110831630A (zh) | 2017-03-01 | 2020-02-21 | 爱尔兰詹森科学公司 | 组合疗法 |
| US11266653B2 (en) | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
| AU2018358160B2 (en) | 2017-11-02 | 2023-03-16 | Abbvie Inc. | Modulators of the integrated stress pathway |
| KR102625224B1 (ko) * | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CA3138123A1 (en) | 2019-05-13 | 2020-11-19 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| MX2021013814A (es) * | 2019-05-13 | 2022-02-10 | Novartis Ag | Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida. |
| WO2021035788A1 (zh) | 2019-08-29 | 2021-03-04 | 中国科学院合肥物质科学研究院 | 吡唑衍生物及其用途 |
| EP4028399B1 (en) | 2019-09-13 | 2024-02-14 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022016021A1 (en) | 2020-07-15 | 2022-01-20 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
| JP2023551434A (ja) | 2020-11-19 | 2023-12-08 | サード ハーモニック バイオ， インコーポレイテッド | 選択的ｃ－ｋｉｔキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法 |
| MX2023010947A (es) | 2021-03-16 | 2023-11-29 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| KR20230158046A (ko) | 2021-03-17 | 2023-11-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항박테리아성 화합물 |
| US20240182495A1 (en) | 2021-03-17 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3234515A1 (en) | 2021-10-28 | 2023-05-04 | Jose Manuel Bartolome-Nebreda | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN120677154A (zh) * | 2022-11-30 | 2025-09-19 | 缆图药品公司 | 用于治疗荨麻疹的作为野生型c-kit激酶抑制剂的n-苯基-吡唑并[1,5-a]吡啶-3-甲酰胺衍生物 |
| JP2025541191A (ja) * | 2022-12-07 | 2025-12-18 | サード ハーモニック バイオ， インコーポレイテッド | Ｃ－ｋｉｔキナーゼ阻害剤としての化合物及び組成物 |
| KR20250129682A (ko) * | 2022-12-07 | 2025-08-29 | 써드 하모닉 바이오, 인크. | C-kit 키나제 억제제로서의 화합물 및 조성물 |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025072330A1 (en) * | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2004001903A2 (en) | 2002-06-20 | 2003-12-31 | Beacon Looms, Inc. | Knitted electrical conductor fabric |
| BRPI0515081B8 (pt) | 2004-09-09 | 2021-05-25 | Natco Pharma Ltd | composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida |
| EP2942349A1 (en) | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| CA2668190A1 (en) * | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| AR083855A1 (es) * | 2010-11-15 | 2013-03-27 | Abbott Lab | Inhibidores de nampt y rock |
| US20130023751A1 (en) | 2011-07-18 | 2013-01-24 | Samuel Victor Lichtenstein | Water retention monitoring |
| BR112014003963A2 (pt) | 2011-09-01 | 2017-03-21 | Irm Llc | compostos e composições como inibidores de quinase c-kit |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| CN104039783A (zh) | 2011-09-01 | 2014-09-10 | Irm责任有限公司 | 作为pdgfr激酶抑制剂的化合物和组合物 |
| JP6134319B2 (ja) | 2011-09-01 | 2017-05-24 | ノバルティス アーゲー | ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物 |
-
2012
- 2012-08-29 JP JP2014528537A patent/JP6134319B2/ja active Active
- 2012-08-29 UY UY34301A patent/UY34301A/es not_active Application Discontinuation
- 2012-08-29 KR KR1020147008107A patent/KR101962495B1/ko active Active
- 2012-08-29 ES ES12756885T patent/ES2761332T3/es active Active
- 2012-08-29 PT PT127568855T patent/PT2751104T/pt unknown
- 2012-08-29 AU AU2012302042A patent/AU2012302042B2/en not_active Ceased
- 2012-08-29 AP AP2014007493A patent/AP2014007493A0/xx unknown
- 2012-08-29 PH PH1/2014/500372A patent/PH12014500372A1/en unknown
- 2012-08-29 PE PE2014000295A patent/PE20140909A1/es not_active Application Discontinuation
- 2012-08-29 SG SG2014014369A patent/SG2014014369A/en unknown
- 2012-08-29 CN CN201280042743.4A patent/CN103797011B/zh active Active
- 2012-08-29 EA EA201490545A patent/EA026152B1/ru not_active IP Right Cessation
- 2012-08-29 BR BR112014004560A patent/BR112014004560A2/pt not_active Application Discontinuation
- 2012-08-29 PL PL12756885T patent/PL2751104T3/pl unknown
- 2012-08-29 CA CA2845169A patent/CA2845169C/en active Active
- 2012-08-29 WO PCT/US2012/052802 patent/WO2013033167A1/en not_active Ceased
- 2012-08-29 MX MX2014002484A patent/MX339937B/es active IP Right Grant
- 2012-08-29 US US13/598,213 patent/US8569283B2/en active Active
- 2012-08-29 EP EP12756885.5A patent/EP2751104B1/en active Active
- 2012-08-31 TW TW101131942A patent/TW201313717A/zh unknown
- 2012-08-31 AR ARP120103223 patent/AR087753A1/es unknown
-
2013
- 2013-09-19 US US14/031,792 patent/US8754071B2/en active Active
-
2014
- 2014-02-17 TN TNP2014000068A patent/TN2014000068A1/en unknown
- 2014-02-17 ZA ZA2014/01175A patent/ZA201401175B/en unknown
- 2014-02-27 GT GT201400034A patent/GT201400034A/es unknown
- 2014-02-27 IL IL231227A patent/IL231227A0/en unknown
- 2014-02-27 CU CU20140024A patent/CU20140024A7/es unknown
- 2014-02-27 CL CL2014000492A patent/CL2014000492A1/es unknown
- 2014-02-28 CO CO14043417A patent/CO6900141A2/es unknown
- 2014-02-28 CR CR20140107A patent/CR20140107A/es unknown
- 2014-03-28 MA MA36864A patent/MA35460B1/fr unknown
- 2014-04-22 US US14/258,963 patent/US9023839B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2014000068A1 (en) | Compounds and compositions as c-kit kinase inhibitors | |
| TN2014000061A1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
| MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| EA201490537A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit | |
| MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
| SG194718A1 (en) | Novel compounds as modulators of protein kinases | |
| MY169987A (en) | Selective pi3k delta inhibitors | |
| TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| BR112014003963A2 (pt) | compostos e composições como inibidores de quinase c-kit | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| PH12013501922A1 (en) | Protein kinase inhibitors |